mRNA cancer vaccines: Advances, trends and challenges.
mRNA cancer vaccines: Advances, trends and challenges.
复制标题
mRNA癌症疫苗：进展，趋势和挑战。
DOI：
10.1016/j.apsb.2022.03.011
复制
发表时间：
2022-07
期刊：
影响因子：
--
通讯作者：
Wang JZ
中科院分区：
文献类型：
--
作者：
He Q;Gao H;Tan D;Zhang H;Wang JZ
患者对信使核糖核酸（mRNA）疫苗表现出良好的耐受性，编码分子的选择是灵活多样的。这些疫苗可以被设计成表达含有多个表位的全长抗原，而不受主要组织相容性复合体（MHC）的限制，相对容易控制，并且可以快速批量生产。美国食品药品监督管理局（FDA）于2021年批准了辉瑞和BioNTech生产的首个基于mRNA的新型冠状病毒病（COVID-19）疫苗，引发了mRNA疫苗研发热潮。基于上述特点和mRNA疫苗的发展，尤其是近五年来，mRNA肿瘤疫苗已成为研究热点，发展迅速。本文从抗原/靶点的选择和表达、载体和佐剂的应用、不同给药途径和临床前评价等方面对mRNA肿瘤疫苗的研究进展进行了分析，以反映mRNA肿瘤疫苗的发展趋势和面临的挑战。本文从抗原/靶点的选择和表达、载体和佐剂的应用、给药途径和临床前评价等方面对mRNA肿瘤疫苗的研究进展进行了综述。
Patients exhibit good tolerance to messenger ribonucleic acid (mRNA) vaccines, and the choice of encoded molecules is flexible and diverse. These vaccines can be engineered to express full-length antigens containing multiple epitopes without major histocompatibility complex (MHC) restriction, are relatively easy to control and can be rapidly mass produced. In 2021, the U.S. Food and Drug Administration (FDA) approved the first mRNA-based coronavirus disease 2019 (COVID-19) vaccine produced by Pfizer and BioNTech, which has generated enthusiasm for mRNA vaccine research and development. Based on the above characteristics and the development of mRNA vaccines, mRNA cancer vaccines have become a research hotspot and have undergone rapid development, especially in the last five years. This review analyzes the advances in mRNA cancer vaccines from various perspectives, including the selection and expression of antigens/targets, the application of vectors and adjuvants, different administration routes, and preclinical evaluation, to reflect the trends and challenges associated with these vaccines. This review analyzes the advances in mRNA cancer vaccines from various perspectives, including the selection and expression of antigens/targets, the application of vectors and adjuvants, administration routes, and preclinical evaluation.
登录
查看更多内容
影响因子：
64.8
作者：
BRENNER, S;MESELSON, M;JACOB, F
通讯作者：
JACOB, F
影响因子：
45.3
作者：
Cesana, GC;DeRaffele, G;Kaufman, HL
通讯作者：
Kaufman, HL
影响因子：
4.4
作者：
Bijker, Martijn S.;van den Eeden, Susan J. F.;van der Burg, Sjoerd H.
通讯作者：
van der Burg, Sjoerd H.
影响因子：
12.4
作者：
Bonehill, Aude;Tuyaerts, Sandra;Thielemans, Kris
通讯作者：
Thielemans, Kris
影响因子：
5.2
作者：
Aurisicchio, Luigi;Ciliberto, Gennaro
通讯作者：
Ciliberto, Gennaro